Fig. 7

Targeting GRK6 potentially suppresses lung metastasis of TNBCs. A Luminescent intensity (upper and middle) and tumor nodules (lower) of luciferase-expression MDA-MB-231 cells in the lungs of tumor-bearing mice treated without (Vehicle, n = 3) or with GRK6-IN-2(n = 4) at 0.25 mg/kg twice a week. B H & E staining for the colonies of the MDA-MB-231 cell variants without with GRK6-IN-2 administration. C Tumor appearance, volume and weight of the MDA-MB-231 cell variants without with GRK6-IN-2 administration. D Western blot analysis for the protein expression of GRK6, β-arrestin 1, β-arrestin 2, p-Erk1/2, Erk1/2, p-NF-κB, NF-κB and GAPDH. GAPDH was used as an internal control of protein loading. E A proposed mechanism for the GRK6-promoted metastatic progression in TNBC